Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives

@article{Yshii2017InflammatoryCD,
  title={Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives},
  author={Lidia Yshii and Reinhard Hohlfeld and Roland S. Liblau},
  journal={Nature Reviews Neurology},
  year={2017},
  volume={13},
  pages={755-763}
}
Cancer treatment strategies based on immune stimulation have recently entered the clinical arena, with unprecedented success. Immune checkpoint inhibitors (ICIs) work by indiscriminately promoting immune responses, which target tumour-associated antigens or tumour-specific mutations. However, the augmented immune response, most notably the T cell response, can cause either direct neurotoxicity or, more commonly, indirect neurotoxic effects through systemic or local inflammatory mechanisms or… 

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors

The aim of this review is to summarize the potential immune-driven pathological mechanisms of NirAEs, which can be extracted from the wide range of neurological auto-inflammatory and autoimmune disorders triggered or exacerbated by ICIs, and the extensive variability of the limited histological findings reported.

Neurological Diseases Associated to Immune Checkpoint Inhibitors

This bibliographic review brings the main neurological diseases associated with therapy, as well as the incidence, symptoms and treatment of monoclonal therapy and checkpoints inhibitors.

Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

The recent progressions in the research of the immune checkpoint molecules and the application of their blocking antibodies in cancer treatment are reviewed, and the cardiac toxicity induced by the therapy and the strategy to monitor, manage this adverse event when it occurs is discussed.

Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy

IrAEs associated with CAR-T and ICPI therapy constitute new entities and early identification and treatment are essential to optimize the functional outcome and further oncologic management of the patient.

Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors

A comprehensive review of the most recent findings in the field of PNSs and AEs, with particular focus on their triggering factors and immunopathogenesis is provided.

Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system

  • M. Dalakas
  • Medicine, Biology
    Therapeutic advances in neurological disorders
  • 2018
The review addresses complications and the applied therapies, discusses immune pathomechanisms including triggering preexisting autoimmunity, highlights the distinction between paraneoplastic and autoimmune etiologies, and identifies uncertainties regarding risk factors.

Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors

An overview of paraneoplastic neurological syndromes, the associations of these conditions with ICI therapy and recommendations for the prevention and management of ICI-associated PNSs are provided.

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

This review extensively searched for susceptible loci associated with various autoimmune diseases, and pooled them in groups most likely to be associated with CPI-induced irAEs, to help guide physicians in a more refined and personal manner.

Case Report: A case of immune checkpoint inhibitor therapy in a patient with multiple sclerosis

A patient with multiple sclerosis who underwent immune checkpoint inhibitor therapy with pembrolizumab for metastatic malignant melanoma who had a complete response to treatment at the cost of MS relapse, which was managed with high-dose steroids.
...

References

SHOWING 1-10 OF 137 REFERENCES

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

The current data regarding immune-related endocrinopathies, including hypophysitis, thyroid dysfunction and diabetes mellitus are described and the clinical management of these endocrineopathies is discussed within the context of the current understanding of the mechanisms of IRAEs.

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Early recognition and treatment of autoimmune encephalitis in patients receiving immune checkpoint blockade therapy will likely be essential for maximizing clinical recovery and minimizing the effect of drug-related toxic effects.

Neurologic complications of immune checkpoint inhibitors

This series highlights the very broad spectrum of neurological complications of ICPIs, emphasizes the need for expedited diagnosis and suggests that withholding treatment early, accompanied with steroid therapy, carries the potential of complete resolution of the neurological immune-mediated condition.

Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease

  • L. Steinman
  • Medicine, Biology
    European journal of immunology
  • 2014
Comparisons between the paraneoplastic syndromes and the new autoimmune conditions seen with antibodies to immune checkpoints at CD152 or at CD279 are likely to illuminate shared mechanisms and solutions to these vexing diseases.

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis

Clinical trial data indicate a frequency of autoimmune encephalitis of ≥0.1 to <1% with a higher probability during combined or sequential anti-CTLA-4/anti- PD-1 therapy than during anti-PD-1 or anti-L1 monotherapy.

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade

Taken together, encephalitic lesions in patients under PD-1/PD-L1 blockade can mimic metastatic brain lesions and this rare irAE has to be considered as a differential diagnosis in patients treated with immunotherapy.

CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.

Increased caution is recommended when using CTLA4 blockade in patients with gynaecological cancers, or malignancies of neuroectodermal origin, such as small cell lung cancer, as such treatment may promote paraneoplastic neurologic disorders.

Limbic encephalitis following immunotherapy against metastatic malignant melanoma

It is advocated considering autoimmune neuroinflammation as a differential for neurological disorders presenting in patients receiving PD-1 antagonist treatment and immunotherapy in general.
...